Cidara Therapeutics Inc (STU:20D0)

€ 21.8 -0.2 (-0.91%) Market Cap: 248.80 Mil Enterprise Value: 130.35 Mil PE Ratio: 0 PB Ratio: 1.44 GF Score: 47/100

Cidara Therapeutics Inc Research & Development Day Transcript
Sep 21, 2023
Cidara Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Cidara Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Cidara Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 15, 2022
Cidara Therapeutics Inc To Host Research And Development Day Transcript
Jul 07, 2022
Cidara Therapeutics Inc To Discuss Data Call Transcript
Dec 14, 2021
Cidara Therapeutics Inc To Host Research And Development Day Webinar Transcript
Sep 21, 2021
Cidara Therapeutics Inc and Janssen Pharmaceuticals Inc Announces Agreement to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza - Conference Call Transcript
Apr 05, 2021
Cidara Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 25, 2020
Cidara Therapeutics, Inc. - Special Call Transcript
Nov 14, 2019
Cidara Therapeutics Inc and Mundipharma International Ltd Form Strategic Partnership to Develop and Commercialize Rezafungin - Conference Call Transcript
Sep 03, 2019
Cidara Therapeutics Inc to Discuss the Phase 2 STRIVE B Results Call Transcript
Jul 29, 2019

Cidara Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript

Sep 11, 2023 / 02:00PM GMT

Release Date Price: €18.2 (+1.00%)

Transcript

Unidentified Participant

Hi. Good morning, everyone. Welcome to the H.C. Wainwright 25th Annual Global Investment Conference. For our next presentation, we have Cidara Therapeutics, and with present CEO, Jeff Stein, here with us today. Thank you for being part of a conference. Please go ahead.

Jeff Stein

Cidara Therapeutics, Inc. - President & CEO

Thomas, thank you for the introduction, and welcome everyone. As mentioned, my name is Jeff Stein, President and CEO of Cidara Therapeutics. I'm going to talk about two programs today. One more briefly, and that's our most advanced program, rezafungin, which is approved for the treatment of invasive candidiasis and candidemia. That was approved in July and is being commercialized in the US by our commercial partner, Melinta; and outside the US and outside Japan by Mundipharma.

Next catalyst in that program we expect is going to be EMA approval, which we expect in the fourth quarter of this year. One feature of all of our programs, both the rezafungin program as well as the Cloudbreak platform is that they create

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.